15th Annual BIO CEO & Investor Conference to Highlight Biotech Outlook, Winning Business Development Models and Timely Therapeutic Topics

• Contact: Abigail Hirsch
• Phone: 202.962.9235
• Email: ahirsch@bio.org

WASHINGTON, D.C. (February 1, 2013) – The Biotechnology Industry Organization(BIO) today announces plenary sessions, Business Roundtables and Therapeutic Workshops selected  for the 15^thannual BIO CEO & Investor Conference. Moderators and panelists chosen to speak represent former White House Chiefs of Staff, industry thought leaders, academics and biopharma executives. The conference, to be held in New York City, February 11 – 12, 2013, is the largest independent investor conference focused on publicly-traded biotechnology companies.

“With more than 600 investors and 150 presenting companies planning to attend, the BIO CEO & Investor Conference serves a vital role in bringing industry leaders together and generating the investment interest that will help bring new therapies to market,” said Alan Eisenberg, BIO’s Executive Vice President of Emerging Companies and Business Development. “This year's program features over 50 thought leaders who will draw from their unparalleled experience in the industry to share their candid insights on what 2013 and beyond will bring.”

The BIO CEO & Investor Conference plenary sessions will forecast both the year ahead in biotech and the political outlook for the next four years. The Business Roundtables will focus on reimbursement, successfully navigating the Chinese market, biopharma collaborations and alternative venues to public markets.  Therapeutic Workshops will address topics the treatment pipeline for pancreatic cancer, chronic lymphocytic leukemia and rare diseases.

Plenary sessions include:

Opening Plenary: Word on the Street: The Buy-Side View for 2013

Monday, February 11^th, 12:00 pm - 12:55 pm

Moderator: Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group

Panelists:

• Samuel D. Isaly, Managing Partner, OrbiMed Advisors
• Oleg Nodelman, Founder & Managing Director, EcoR1 Capital
• Nathan Sadeghi-Nejad, Partner, Palkon Capital Management

Closing Plenary: Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff

Tuesday, February 12^th, 4:00 pm – 4:55 pm

Moderator: James C. Greenwood, President & CEO, BIO

Panelists:

• Joshua Bolten, 22^ndWhite House Chief of Staff and Managing Director, Rock Creek Global Advisors
• John Podesta, Former White House Chief of Staff and Founder and Chair, Center for American Progress

Business Roundtables include:

Show Me the Money: Reimbursement in an ACA World

Monday, February 11^th, 9:00 am – 9:55 am

Moderator: Roger Longman, Chief Executive Officer, Real Endpoints

Panelists:

• Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center
• Rena Conti, PhD, Assistant Professor of Health Policy & Economics, University of Chicago
• Ed Pezalla, MD, MPH, National Medical Director for Pharmacy Policy and Strategy, Office of the Chief Medical Officer, Aetna
• Cynthia Smith, Vice President, Market Access & Commercial Development, Affymax

How the Other Half Lives: What’s Happening in Venture and Why it Matters

Monday, February 11^th, 2:00 pm – 2:55 pm

Moderator: Jeffrey Baumel, Partner, SNR Denton

Panelists:

• Arlene M. Morris, Chief Executive Officer, Syndax Pharmaceuticals
• Stelios Papadopoulos, PhD, Chairman, Exelixis, Inc.
• Dennis Purcell, Senior Managing Partner, Aisling Capital
• David Sable, Portfolio Manager, Special Situations Fund

Small Companies Thinking Big – China Tactical Strategies

Monday, February 11^th, 3:30 pm – 4:25 pm

Moderator: Jimmy Zhang, PhD, MBA, Managing Director, MSD Early Investments--Greater China, Merck & Co. Inc.

Panelists:

• Friedhelm Blobel, PhD, President, CEO & Director, SciClone Pharmaceuticals
• Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development, BIO
• Kewen Jin, Managing Director, Nimbus Innoworks
• Laurence Reid, PhD, Senior Vice President & Chief Business Officer, Alnylam Pharmaceuticals

Putting a Ring on It – When Drug Development Partnerships Become Acquisitions

Tuesday, February 12^th, 12:00 pm – 12:55 pm

Moderator: Jeff Stewart, Senior Engagement Manager, Campbell Alliance

Panelists:

• Michael Gilman, PhD, Senior Vice President, Early Stage Programs, Biogen Idec
• Demetrios Kydonieus, Esq, Vice President, Strategy Alliances and Transactions, Bristol Myers-Squibb Company
• Michael Margolis, R.Ph., Managing Director, ROTH Capital Partners
• Effie Toshav, Partner, Corporate, Fenwick & West LLP

The Road Less Traveled: Alternative Avenues to Public Markets

Tuesday, February 12^th, 1:30 pm – 2:25 pm

Moderator: William Hicks, Member, Mintz Levin

Panelists:

• Charles Crain, Manager, Policy & Research, BIO
• Michelle Dipp, MD, PhD, Chief Executive Officer & Co-Founder, OvaScience
• Daniel B. Dubin, MD, Vice Chairman, Founder of MEDACorp, Leerink Swann
• Peter Kolchinsky, PhD, Managing Partner, RA Capital

Therapeutic Workshops include:

Oncology: Panning for Gold – Prospecting the Pancreatic Pipeline

Monday, February 11^th, 10:30 am – 11:25 am

Moderator: Brian Klein, MD, Vice President & Senior Biotechnology Analyst, Stifel Nicolaus

Panelists:

• John Chabot, MD, FACS, Chief, Division of GI/Endocrine Surgery and Executive Director, Pancreas Center, New York Presbyterian Hospital/Columbia University
• Stewart M. Kroll, Senior Vice President, Clinical Operations and Biostatistics, Threshold Pharmaceuticals
• Peter Laivins, Vice President, Late Stage Drug Development, Merrimack Pharmaceuticals
• Kenneth H. Yu, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center

Orphan Drugs: Making Rare Diseases Rarer

Tuesday, February 12^th, 9:00 am – 9:55 am

Moderator: Ritu S. Baral, Principal, Sr. Analyst – Biotechnology Equity Research, Canaccord Genuity

Panelists:

• Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals
• John F. Crowley, Chairman & CEO, Amicus Therapeutics
• Pamela Gavin, Senior Vice President, National Organization for Rare Disorders (NORD)
• Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa
• Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit

Oncology: The CLL Chronicles – The Next Chapter in Clinical Developments

Tuesday, February 12^th, 12:00 pm – 12:55 pm

Moderator: Joel Sendek, Managing Director & Biotechnology Analyst, Stifel Nicolaus & Company

Panelists:

• Jacqueline Barrientos, MD, Assistant Professor of Medicine, Hofstra North Shore-LIJ School of Medicine CLL Research and Treatment Program
• John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist, Memorial Sloan-Kettering Cancer Center
• Kanti Rai, MD, Joel Finkelstein Cancer Foundation Professor of Medicine and Professor of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine

Additionally, the event will feature the BIO One-on-One Partnering™ system which provides the opportunity to arrange meetings between investors, companies and industry executives. Furthermore, the event features presentations from more than 150 leading biotechnology and pharmaceutical companies.

Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors. Media registration is complimentary for credentialed members of the media.All registrations are subject to verification of credentials.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors. The supporting bank sponsors include: Stifel Nicolaus & Company, Leerink Swann and ROTH Capital Partners, LLC.

To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here. 

###